206 related articles for article (PubMed ID: 27378505)
21. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model.
Mbalaviele G; Dunstan CR; Sasaki A; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 1996 Sep; 56(17):4063-70. PubMed ID: 8752180
[TBL] [Abstract][Full Text] [Related]
22. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF.
Park BK; Zhang H; Zeng Q; Dai J; Keller ET; Giordano T; Gu K; Shah V; Pei L; Zarbo RJ; McCauley L; Shi S; Chen S; Wang CY
Nat Med; 2007 Jan; 13(1):62-9. PubMed ID: 17159986
[TBL] [Abstract][Full Text] [Related]
23. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
[TBL] [Abstract][Full Text] [Related]
24. Cryoprotective isoliquiritigenin-zein phosphatidylcholine nanoparticles inhibits breast cancer-bone metastasis by targeting JAK-STAT signaling pathways.
Ganesan K; Xu C; Xie C; Sui Y; Zheng C; Gao F; Chen J
Chem Biol Interact; 2024 Jun; 396():111037. PubMed ID: 38719172
[TBL] [Abstract][Full Text] [Related]
25. Estradiol enhances osteolytic lesions in mice inoculated with human estrogen receptor-negative MDA-231 breast cancer cells in vivo.
Winding B; Misander H; Høegh-Andersen P; Brünner N; Foged NT
Breast Cancer Res Treat; 2003 Mar; 78(2):205-16. PubMed ID: 12725420
[TBL] [Abstract][Full Text] [Related]
26. Plumbagin attenuates cancer cell growth and osteoclast formation in the bone microenvironment of mice.
Yan W; Wang TY; Fan QM; Du L; Xu JK; Zhai ZJ; Li HW; Tang TT
Acta Pharmacol Sin; 2014 Jan; 35(1):124-34. PubMed ID: 24384612
[TBL] [Abstract][Full Text] [Related]
27. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.
Hiraga T; Kizaka-Kondoh S; Hirota K; Hiraoka M; Yoneda T
Cancer Res; 2007 May; 67(9):4157-63. PubMed ID: 17483326
[TBL] [Abstract][Full Text] [Related]
28. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development.
Yin JJ; Selander K; Chirgwin JM; Dallas M; Grubbs BG; Wieser R; Massagué J; Mundy GR; Guise TA
J Clin Invest; 1999 Jan; 103(2):197-206. PubMed ID: 9916131
[TBL] [Abstract][Full Text] [Related]
29. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis.
Park HR; Min SK; Cho HD; Kim DH; Shin HS; Park YE
J Korean Med Sci; 2003 Aug; 18(4):541-6. PubMed ID: 12923331
[TBL] [Abstract][Full Text] [Related]
30. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity.
Pederson L; Winding B; Foged NT; Spelsberg TC; Oursler MJ
Cancer Res; 1999 Nov; 59(22):5849-55. PubMed ID: 10582709
[TBL] [Abstract][Full Text] [Related]
31. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer.
Hiraga T; Myoui A; Choi ME; Yoshikawa H; Yoneda T
Cancer Res; 2006 Feb; 66(4):2067-73. PubMed ID: 16489006
[TBL] [Abstract][Full Text] [Related]
32. Future treatment of bone metastases.
Lipton A
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6305s-6308s. PubMed ID: 17062719
[TBL] [Abstract][Full Text] [Related]
33. Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells.
Pratap J; Wixted JJ; Gaur T; Zaidi SK; Dobson J; Gokul KD; Hussain S; van Wijnen AJ; Stein JL; Stein GS; Lian JB
Cancer Res; 2008 Oct; 68(19):7795-802. PubMed ID: 18829534
[TBL] [Abstract][Full Text] [Related]
34. Transforming growth factor-beta in osteolytic breast cancer bone metastases.
Guise TA; Chirgwin JM
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S32-8. PubMed ID: 14600590
[TBL] [Abstract][Full Text] [Related]
35. A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis.
Harms JF; Welch DR; Samant RS; Shevde LA; Miele ME; Babu GR; Goldberg SF; Gilman VR; Sosnowski DM; Campo DA; Gay CV; Budgeon LR; Mercer R; Jewell J; Mastro AM; Donahue HJ; Erin N; Debies MT; Meehan WJ; Jones AL; Mbalaviele G; Nickols A; Christensen ND; Melly R; Beck LN; Kent J; Rader RK; Kotyk JJ; Pagel MD; Westlin WF; Griggs DW
Clin Exp Metastasis; 2004; 21(2):119-28. PubMed ID: 15168729
[TBL] [Abstract][Full Text] [Related]
36. PTHrP regulates angiogenesis and bone resorption via VEGF expression.
Isowa S; Shimo T; Ibaragi S; Kurio N; Okui T; Matsubara K; Hassan NM; Kishimoto K; Sasaki A
Anticancer Res; 2010 Jul; 30(7):2755-67. PubMed ID: 20683010
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer bone metastasis and current small therapeutics.
Cicek M; Oursler MJ
Cancer Metastasis Rev; 2006 Dec; 25(4):635-44. PubMed ID: 17160709
[TBL] [Abstract][Full Text] [Related]
38. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.
Morony S; Capparelli C; Sarosi I; Lacey DL; Dunstan CR; Kostenuik PJ
Cancer Res; 2001 Jun; 61(11):4432-6. PubMed ID: 11389072
[TBL] [Abstract][Full Text] [Related]
39. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
Buijs JT; Henriquez NV; van Overveld PG; van der Horst G; Que I; Schwaninger R; Rentsch C; Ten Dijke P; Cleton-Jansen AM; Driouch K; Lidereau R; Bachelier R; Vukicevic S; Clézardin P; Papapoulos SE; Cecchini MG; Löwik CW; van der Pluijm G
Cancer Res; 2007 Sep; 67(18):8742-51. PubMed ID: 17875715
[TBL] [Abstract][Full Text] [Related]
40. Tie2 signaling regulates osteoclastogenesis and osteolytic bone invasion of breast cancer.
Min Y; Ren X; Vaught DB; Chen J; Donnelly E; Lynch CC; Lin PC
Cancer Res; 2010 Apr; 70(7):2819-28. PubMed ID: 20233869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
